Bio-Rad's study demonstrating utility of its SpyLock technology for fast generation and screening of bispecific antibodies

Study Describes Method to Successfully Modify the Functional Activity of SpyCatcher Protein for the Rapid Generation and High-Throughput Screening of Bispecific Antibodies

Hercules, Calif. — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announces the publication of a peer-reviewed study in Nature Communications, “Engineered Reversible Inhibition of SpyCatcher Reactivity Enables Rapid Generation of Bispecific Antibodies”¹. The study demonstrates the utility of Bio-Rad’s SpyLock technology for the rapid generation and screening of bispecific antibodies, allowing greatly accelerated functional validation of bispecifics and identification of the most promising candidates.

The study describes the method used to successfully engineer functional control into SpyCatcher protein, resulting in a reversibly inhibitable mutant, termed SpyLock (SL), which is in turn fused to regular SpyCatcher (SC) to create BiLockCatcher protein — an SL-SC dimer offering an accelerated route to bispecific antibody generation. The proprietary SpyLock technology significantly expands the toolbox for the modular construction of antibodies based on SpyTag/SpyCatcher protein ligation system, Bio-Rad’s new rapid bispecific generation and screening service, launched earlier this year², is based on SpyLock protein technology and provided as part of its Pioneer™ Antibody Discovery Platform. The service enables customers to identify effective antibody combinations to take forward into drug development.

The Pioneer Platform features a fully human synthetic phage display library engineered to include more than 200 billion unique sequences and to be capable of identifying high-affinity antibody candidates using Bio-Rad’s SpyDisplay selection technology. With proprietary TrailBlazer™ technology, the Pioneer Platform provides prototypes of therapeutic antibodies in a multitude of formats for streamlined lead identification. The final antibodies are fully mammalian expressed IgGs, functionally characterized with a complete data package and sequence.

“The therapeutic potential and efficacy of bispecific antibodies is widely acknowledged. Our SpyLock strategy generates bispecific antibodies in a single, scalable format, facilitating the screening of a large number of antibody combinations. The service streamlines and accelerates the generation of bispecific antibodies in as a little as 90 minutes,” said John Cardone, Marketing Manager, Custom Antibodies, Life Science Group, Bio-Rad. “Demonstration of this methodology and its publication in a high-profile journal is a testament to the quality of our innovative approach and scientific team, which we are pleased to offer to customers as part of our Pioneer Antibody Discovery Platform.”

 To learn more about the Bio-Rad Pioneer Antibody Discovery Platform and SpyLock services, visit bio-rad-antibodies.com/SpyLockPioneer.

1. Hentrich C et al. (2024). Engineered Reversible Inhibition of SpyCatcher Reactivity Enables Rapid Generation of Bispecific Antibodies. Nat Commun 15, 5939
2. Bio-Rad (2024). Bio-Rad Adds Rapid Bispecific Antibody Prototyping and Screening Services to Pioneer Antibody Discovery Platform, press release July 29, 2024.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. PIONEER and TRAILBLAZER are trademarks of Bio-Rad Europe GmbH in certain jurisdictions.  

To learn more, visit bio-rad.com.

Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.